Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 17/20 | 0.47 |
| ▸ | PIK3R2 | O00459 | 7/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.47 |
| ▸ | STS | P08842 | 1/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17330717 | 1.00 | PIK3CD (0.47) | PIK3CDPIK3R2OPRM1OPRD1OGFRL1 | |
| SCHEMBL17330820 | 0.97 | OPRM1 (0.48) | PIK3CDPIK3R2OPRM1OPRD1OGFRL1 | |
| SCHEMBL17330951 | 0.95 | PIK3CD (0.44) | PIK3CDPIK3R2OPRM1OPRD1OGFRL1 | |
| SCHEMBL17330565 | 0.95 | PIK3CD (0.44) | PIK3CDPIK3R2OPRM1OPRD1OGFRL1 | |
| SCHEMBL17330563 | 0.95 | PIK3CD (0.44) | PIK3CDPIK3R2OPRM1OPRD1OGFRL1 | |
| SCHEMBL22854505 | 0.91 | PIK3CD (0.46) | PIK3CDPIK3R2OPRM1OPRD1OGFRL1 | |
| SCHEMBL17330844 | 0.91 | PIK3CD (0.45) | PIK3CDPIK3R2OPRM1OPRD1OGFRL1 | |
| SCHEMBL17330842 | 0.91 | PIK3CD (0.45) | PIK3CDPIK3R2OPRM1OPRD1OGFRL1 | |
| SCHEMBL17331031 | 0.90 | PIK3CD (0.45) | PIK3CDPIK3R2OPRM1OPRD1OGFRL1 | |
| SCHEMBL17331032 | 0.90 | PIK3CD (0.45) | PIK3CDPIK3R2OPRM1OPRD1OGFRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3154958-B1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD SCIENCES INC (US) | 2020-10-07 | — | — | EP | disclosed |
| US-10092563-B2 | Phosphatidylinositol 3-kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2018-10-09 | — | — | US | disclosed |
| US-20150361054-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD SCIENCES, INC. | 2015-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361054-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PIK3CA, AKT3, PIK3CB | PIK3CD 5/4885PIK3R2 22/4885OPRM1 816/4885 |
| US-10092563-B2 | Phosphatidylinositol 3-kinase inhibitors | PIK3CA, AKT3, PIK3CB | PIK3CD 5/4885PIK3R2 22/4885OPRM1 816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.